How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,414 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Diabetes, Pre-Diabetes and Cardiovascular Diseases

: COllaborative analysis of Diagnostic criteria in Europe DES drug-eluting stent DETECT-2 The Evaluation of Screening and Early Detection Strategies for T2DM and IGT DIABHYCAR Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events and Ramipril DIAMOND Danish Investigations and Arrhythmia ON Dofe- tilide DIG Digitalis Investigation Group DIGAMI Diabetes and Insulin–Glucose Infusion in Acute Myocardial Infarction DIRECT DIabetic REtinopathy Candesartan Trials DM diabetes mellitus DPP-4 (...) and ‘gestational DM’ (Table 3). 2 Type 1 diabetes is characterized by de?ciency of insulin due to destruction of pancreatic beta-cells, progressing to absolute insulin de?ciency. Typically, T1DM occurs in young, slim individuals present- ing with polyuria, thirst and weight loss, with a propensity to ketosis. However, T1DM may occur at any age, 11 sometimes with slow pro- gression. In the latter condition, latent auto-immune DM in adults (LADA), insulin dependence develops over a few years. People who have

2013 European Society of Cardiology

102. Tissue-Muscle Perfusion Scintigraphy of the Lower Limbs in a Patient with Type 2 Diabetes Mellitus and Peripheral Arterial Disease Full Text available with Trip Pro

in basal conditions ("rest" study) and exercise conditions ("stress" study). Emphasis is given on perfusion reserve (PR) as an important indicator of preservation of microcirculation and its local autoregulatory mechanisms in PAD. We present a case of a 71-year-old male diabetic patient with skin ulcers of the right foot and an ankle-brachial index >1.2 (0.9-1.1). Dynamic phase TMPS of the lower limbs showed decreased and late arterial vascularization of the right calf (RC) with lower percentage (...) Tissue-Muscle Perfusion Scintigraphy of the Lower Limbs in a Patient with Type 2 Diabetes Mellitus and Peripheral Arterial Disease The estimation of tissue perfusion as a hemodynamic consequence of peripheral arterial disease (PAD) in diabetic patients is of great importance in the management of these patients.We present a noninvasive, functional method of 99mTc-MIBI (methoxy-isobutyl-isonitrile) tissue-muscle perfusion scintigraphy (TMPS) of the lower limbs, which assesses tissue perfusion

2016 Molecular Imaging and Radionuclide Therapy

103. A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

. ClinicalTrials.gov Identifier: NCT02933853 Recruitment Status : Completed First Posted : October 14, 2016 Last Update Posted : January 8, 2018 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects with Type 2 Diabetes Mellitus Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 (...) A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies

2016 Clinical Trials

104. Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

in HbA1c Change from baseline in 2-hour postprandial glucose (PPG) following a mixed meal; Change from baseline in body weight; Change from baseline in SBP for all patients. To evaluate the safety of sotagliflozin doses 1 and 2 versus placebo. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Sotagliflozin (SAR439954) Drug: Placebo Phase 3 Detailed Description: Up to 34 weeks, including a Screening Period consisting of a Screening Phase of up to 2 weeks and a 2-week (...) Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2016 Clinical Trials

105. Polyneuropathy in Diabetes Mellitus Type 2

Polyneuropathy in Diabetes Mellitus Type 2 Polyneuropathy in Diabetes Mellitus Type 2 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Polyneuropathy in Diabetes Mellitus Type 2 The safety and scientific (...) Description Go to Brief Summary: This is a population-based study of type 2 diabetes patients with and without neuropathy recruited from the Danish National Type 2 Diabetes cohort (DD2). Perspective: The study will identify risk factors for developing diabetic polyneuropathy and painful diabetic polyneuropathy and provide information on the underlying mechanisms, which will hopefully contribute to significant improvements in the treatment and prevention of diabetic polyneuropathy in future. Condition

2016 Clinical Trials

106. A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

-in. On Day 4, each subject will be randomized to a treatment sequence that will include three treatment assignments for each of three treatment Periods according to the randomization scheme. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: ORMD-0801 (qd) Drug: ORMD-0801 (bid) Drug: ORMD-0801 (tid) Other: Placebo Phase 2 Detailed Description: Following the screening, eligible subjects entered a 3-day, single-blind placebo run-in. On Day 4, each subject was randomized (...) : July 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Keywords provided by Oramed, Ltd.: Oral Insulin DM T2 (Diabetes Mellitus Type 2) Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Insulin Insulin, Globin Zinc Hypoglycemic Agents Physiological Effects of Drugs

2016 Clinical Trials

107. Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: semaglutide Drug: sitagliptin Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 500 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Efficacy (...) Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2016 Clinical Trials

108. A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Description Go to Brief Summary: The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM) Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: LGD-6972-5 mg Drug: LGD-6972-10 mg Drug: LGD-6972-15 mg Other: Placebo Phase 2 Detailed Description: This will be a 12-week, randomized, double-blind, placebo-controlled, 4 (...) and 40 kg/m2, inclusive, and must weigh more than 45 kg Exclusion Criteria: History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent hypoglycemia or hypoglycemia unawareness Women of childbearing potential, lactating, or has a positive pregnancy test History or presence of alcoholism or drug abuse within 2 years prior to screening Unwilling to comply with study restrictions, including restrictions on strenuous exercise Presence of any of the following conditions: renal

2016 Clinical Trials

109. Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

: NCT02906930 Recruitment Status : Completed First Posted : September 20, 2016 Last Update Posted : October 10, 2018 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only. Condition or disease Intervention/treatment (...) Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2016 Clinical Trials

110. Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)

in hemoglobin A1C (HbA1c) compared with placebo as assessed by change from baseline to Week 16 [Phase A (double-blind period)]. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Omarigliptin Drug: Placebo Biological: Insulin Phase 4 Detailed Description: After a screening period of up to 2 weeks followed by a pretreatment period of 2 or 10 weeks, each participant will be receiving assigned double-blind treatment (omarigliptin 25 mg or placebo once weekly) for approximately 16 (...) Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039) Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2016 Clinical Trials

111. A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus

A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record (...) managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus The safety and scientific

2016 Clinical Trials

112. A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre- ix/Combination I

-diabetic drugs Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: Insulin degludec/liraglutide Drug: Insulin degludec Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 210 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: This Trial is Conducted in Asia. The Aim of This Trial (...) A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre- ix/Combination I A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix

2016 Clinical Trials

113. A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus

drug in the body), and Safety of NNC0143-0406 in Subjects with Type 1 Diabetes Mellitus Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 1 Drug: NNC0143-0406 Drug: Insulin Aspart Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 47 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official (...) A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2016 Clinical Trials

114. Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM) Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2016 Clinical Trials

115. Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.

: March 7, 2018 Sponsor: Takeda Information provided by (Responsible Party): Takeda Study Details Study Description Go to Brief Summary: The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes. Condition or disease Intervention/treatment Diabetes Mellitus, Type 2, Cancer Drug: Pioglitazone Detailed Description: The study enroll a large population (...) registry Diabetes Mellitus (DM) registry, aged 40 years or older and are members of KPNC as of January 1, 1997, or has been in the DM registry, reached aged 40 years between January 1, 1997 and June 30, 2005 and are KPNC members on their 40th birthday, or has joined KPNC after January 1, 1997, aged 40 years or older when they are identified by the DM registry between January 1, 1997 and June 30, 2005. Exclusion Criteria: 1. Age less than (<) 40 years during study period. 2. No KPNC medication benefits

2016 Clinical Trials

116. Use of Stem Cells in Diabetes Mellitus Type 1

-Adwan, University of Jordan Study Details Study Description Go to Brief Summary: Allogenic adipose derived mesenchymal stem cells will be injected into patients newly diagnosed with type 1 Diabetes Mellitus Condition or disease Intervention/treatment Phase Diabetes Mellitus Type 1 Biological: Adipose mesenchymal cells with bone marrow mononuclear cells Phase 1 Detailed Description: Adipose derived mesenchymal stem cells (ASCs) are to be collected from blood group O donor, cells will be passaged (...) Patients with Type 1 Diabetes Mellitus. Age from 18 years to 35 years either gender. Duration of disease: not exceeding 3 years unless C-peptide is not less than 0.5 ng/ml C-Peptide at inclusion base line should not be less than 0.5 ng/ml No clinical evidence of renal, retinal, vascular or skin complications Body Mass Index not exceeding 30 Any HbA1c At least one positive antibody either anti-Glutamic Acid Decarboxylase-65 or Insulinoma-Associated-2 Autoantibodies (anti-1A2) Informed Consent by patient

2016 Clinical Trials

117. Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Identifier: NCT02963922 Recruitment Status : Completed First Posted : November 15, 2016 Last Update Posted : October 26, 2018 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin. Condition or disease (...) Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning

2016 Clinical Trials

118. Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

ratio to either Albiglutide active liquid auto-injector (LAI) plus Placebo lyophilized DCC pen injector (lyophilized DCC PI); or, Albiglutide lyophilized DCC PI plus Placebo LAI. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Lyophilized albiglutide DCC pen injector Drug: Lyophilized albiglutide DCC pen injector matching placebo Drug: Albiglutide liquid auto-injector Drug: Albiglutide liquid auto-injector matching placebo Phase 3 Study Design Go to Layout table (...) Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2016 Clinical Trials

119. Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

, tolerability and immunogenicity data for the albiglutide liquid drug product. This extension study will comprise 2 study periods: treatment (26 weeks) and post-treatment follow-up (8 weeks). A maximum of 300 subjects will be eligible to take part in this extension study. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Albiglutide Device: Auto-injector Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual (...) Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2016 Clinical Trials

120. A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps

: Eli Lilly and Company Information provided by (Responsible Party): Eli Lilly and Company Study Details Study Description Go to Brief Summary: This study will evaluate a blood sugar lowering insulin, LY900014, delivered by an insulin pump continuously under the skin. The study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014 and its effect on blood sugar levels when it is delivered via an insulin pump. Side effects and tolerability (...) will be documented. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 1 Drug: LY900014 Drug: Insulin Lispro Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 28 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Basic Science Official Title: Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>